title: A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.
abstract: Epidemiological data link erectile dysfunction (ED) and benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS), two highly prevalent conditions in aging men, assuming common pathophysiological pathways. Tadalafil 5 mg once daily has been approved for the treatment of men with LUTS with or without comorbid ED. The aim of this review is to provide an overview of current knowledge on the epidemiological and pathophysiological links between ED and LUTS and to focus on tadalafil as a new treatment option in men with BPH-associated LUTS. A Medline search was completed using the Medical Subject Headings (MESH® keywords) 'prostatic hyperplasia' and 'phosphodiesterase inhibitors'. This search revealed 125 relevant references (entire Medline database up to 11 March 2014). The efficacy of tadalafil 5 mg once daily for the treatment of LUTS has been reported by several well-designed studies. Tadalafil improves significantly the total International Prostate Symptom Score (IPSS), the voiding and storage subscores, the IPSS Quality of Life (QoL) and the BPH Impact Index (BII). Its efficacy is irrelevant to the erectile function status of the patients. However, in the majority of these studies tadalafil is not associated with improvement in maximum urine flow or post-void residual volume (PVR). Its safety profile is well established and no new or unexpected adverse events other than those reported in ED studies have been recorded. Tadalafil is today a new treatment alternative to other established drugs for LUTS such as the α-adrenergic antagonists or 5α-reductase inhibitors. However, it is not just an alternative, since sexual adverse events associated with these drugs are avoided and tadalafil is the only drug that can treat both ED and LUTS at the same time.
authors.affiliation: 2 Department of Urology, General Hospital 'Papageorgiou', Aristotle University of Thessaloniki, Kimiseos Theotokou 26B, Pefka, Thessaloniki, 54006 Thessaloniki, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Hatzimouratidis
keywords: erectile dysfunction; lower urinary tract symptoms; phosphodiesterase inhibitors; prostatic hyperplasia
references.citation: Endocrinology. 2007 Mar;148(3):1019-29
references.pmid: 17138653
references.citation: Eur Urol. 2010 May;57(5):804-14
references.pmid: 20189712
references.citation: J Urol. 2014 Feb;191(2):405-11
references.pmid: 24096120
references.citation: Eur Urol. 2005 Jun;47(6):838-45
references.pmid: 15925081
references.citation: Int J Impot Res. 2003 Aug;15(4):253-7
references.pmid: 12934052
references.citation: Urology. 2006 Jun;67(6):1199-204
references.pmid: 16765179
references.citation: J Sex Med. 2013 Aug;10(8):2044-52
references.pmid: 23782459
references.citation: Eur Urol. 2006 Dec;50(6):1153-6
references.pmid: 17045387
references.citation: J Sex Med. 2008 Apr;5(4):935-945
references.pmid: 18221277
references.citation: Urology. 2009 Jun;73(6):1397-401
references.pmid: 19285714
references.citation: Eur Urol. 2008 Jun;53(6):1236-44
references.pmid: 18281145
references.citation: J Sex Med. 2005 May;2(3):438-44
references.pmid: 16422877
references.citation: J Sex Med. 2008 Sep;5(9):2170-8
references.pmid: 18638006
references.citation: Eur Urol. 2010 Mar;57(3):522-8
references.pmid: 19185976
references.citation: Urology. 2001 Apr;57(4):763-8
references.pmid: 11306400
references.citation: J Urol. 2014 Mar;191(3):727-33
references.pmid: 24096118
references.citation: Int J Impot Res. 2007 Nov-Dec;19(6):544-50
references.pmid: 17611608
references.citation: BJU Int. 2003 Nov;92(7):719-25
references.pmid: 14616454
references.citation: J Sex Med. 2011 Oct;8(10):2746-60
references.pmid: 21812935
references.citation: Eur Urol. 2011 Nov;60(5):1105-13
references.pmid: 21871706
references.citation: Eur Urol. 2004 Aug;46(2):229-34
references.pmid: 15245818
references.citation: J Urol. 2005 Jul;174(1):205-9; discussion 209
references.pmid: 15947628
references.citation: Eur Urol. 2011 Feb;59(2):272-9
references.pmid: 21036463
references.citation: J Urol. 2008 Jun;179(6):2321-6
references.pmid: 18423761
references.citation: J Sex Med. 2012 Jan;9(1):271-81
references.pmid: 21981682
references.citation: Eur Urol. 2005 Jun;47(6):824-37
references.pmid: 15925080
references.citation: Neurourol Urodyn. 2011 Mar;30(3):292-301
references.pmid: 21284024
references.citation: Urology. 2012 Apr;79(4):875-82
references.pmid: 22341603
references.citation: J Am Geriatr Soc. 2001 Apr;49(4):436-42
references.pmid: 11347788
references.citation: BJU Int. 2013 Nov;112(7):990-7
references.pmid: 23937669
references.citation: BJU Int. 2011 Apr;107(7):1110-6
references.pmid: 21244606
references.citation: Int Urol Nephrol. 2013 Feb;45(1):39-43
references.pmid: 23108604
references.citation: J Sex Med. 2013 Mar;10(3):857-65
references.pmid: 23346990
references.citation: Urology. 2003 Jan;61(1):201-6
references.pmid: 12559296
references.citation: Radiol Med. 2009 Oct;114(7):1106-14
references.pmid: 19697101
references.citation: J Urol. 2007 Apr;177(4):1401-7
references.pmid: 17382741
references.citation: J Urol. 2007 Mar;177(3):1071-7
references.pmid: 17296414
references.citation: J Urol. 2008 Oct;180(4):1228-34
references.pmid: 18722631
references.citation: Eur Urol. 2012 May;61(5):917-25
references.pmid: 22297243
references.citation: Eur Urol. 2011 Oct;60(4):809-25
references.pmid: 21726934
references.citation: BJU Int. 2007 Feb;99(2):347-54
references.pmid: 17313423
references.citation: J Neurophysiol. 2001 Jul;86(1):304-11
references.pmid: 11431511
references.citation: Urol Int. 2013;91(1):10-8
references.pmid: 23816815
references.citation: BJU Int. 2008 Mar;101 Suppl 3:22-6
references.pmid: 18307682
references.citation: J Urol. 2008 Jan;179(1):250-5; discussion 255
references.pmid: 18001787
references.citation: Urology. 2013 Sep;82(3):667-73
references.pmid: 23876588
references.citation: Int J Impot Res. 2007 May-Jun;19(3):317-20
references.pmid: 17080093
references.citation: Eur Urol. 2009 Jan;55(1):38-48
references.pmid: 18783872
references.citation: Eur Urol. 2003 Dec;44(6):637-49
references.pmid: 14644114
references.citation: Urology. 2010 Jun;75(6):1452-8
references.pmid: 20163842
references.citation: Eur Urol. 2003 Nov;44(5):588-94
references.pmid: 14572759
references.citation: J Urol. 2010 Mar;183(3):1092-7
references.pmid: 20092847
references.citation: Int J Impot Res. 2000 Dec;12(6):305-11
references.pmid: 11416833
references.citation: Eur Urol. 2009 Oct;56(4):727-35
references.pmid: 19409693
references.citation: J Urol. 2001 Aug;166(2):569-74; discussion 574-5
references.pmid: 11458070
references.citation: JAMA. 1999 Feb 10;281(6):537-44
references.pmid: 10022110
references.citation: BJU Int. 2007 Oct;100(4):813-9
references.pmid: 17822462
references.citation: BJU Int. 2010 Feb;105(4):502-7
references.pmid: 19732051